NCT06776224Completed
Visual (Path)Ways in Multiple Sclerosis - Part II
Evaluation of Neuroaxonal Loss Outside of Any Inflammation in Multiple Sclerosis by a Multimodal Study of the Visual Pathways Model
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
Multiple sclerosis (MS) is an inflammatory demyelinating and degenerative disease of the central nervous system. The mechanisms of neuro-axonal loss remain incompletely elucidated. An acute demyelinating lesion will produce both immediate and delayed axonal loss. Immediate axonal loss is linked to the occurrence of axonal transection. Delayed axonal loss is the cause of axonal degeneration in progressive MS. Visual impairment is common in the disease (vision, oculomotricity, cognition). Through a longitudinal multimodal analysis of visual pathways, we would like to investigate physiopathological mechanisms leading to neurodegenerative process and visual impairment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 64 (actual)
- First submitted
- 9 Jan 2025
- Start date
- 24 Jan 2025
- Primary completion date
- 24 Apr 2026
- Lead sponsor
- University Hospital, Lille
- Diseases
- Multiple sclerosis
- NCT number
- NCT06776224
What you commit to
- Study type: Interventional
- Participants enrolled: 64
- From 24 Jan 2025 to the primary completion date, 24 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to MRI (claustrophobia, incompatible metal foreign bodies such as certain pacemakers and mechanical valves, cochlear implants, intra-orbital metal splinters, pregnancy, certain brands of IUD because of the 3 Tesla magnetic field).
Other illness
- Other neurological pathologies that may interfere with MRI and/or OCT data (diabetes, retinopathy \[any cause\], glaucoma, retinal detachment, ametropia \> 6 diopters)
Lab values
- Contraindication to injection: severe renal failure with creatine clearance \<30, allergy to contrast media, pregnancy, breast-feeding.
Age
- Age \< 18 years
Other
- Pregnant women
- Nursing women
- Persons incapable of giving consent on their own, with or without legal protection (guardianship/curatorship)
- Person under legal protection
- Persons deprived of their liberty
- Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent form
Who the study is looking for
- Male and/or female participants in the VWIMS research project
- At least 18 years of age at the time of inclusion in VWIMS - II
- Patient having given written consent to participate in the study
- Socially insured patient
- Patient willing to comply with all study procedures and duration
Criteria the registry did not label
- Patients with relapsing-remitting multiple sclerosis receiving high-efficacy or non-high-efficacy treatment and follow-up at the CRCSEP of the Lille University Hospital through past participation in the VWIMS study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Direction de la Recherche et de l'innovation (DRI) 6 rue Professeur Laguesse Coordinator of this site? Confirm its status | Lille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.